Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Long Search Ends For Sanofi As It Buys Universal Medicare's Nutraceutical Brands In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - French drug maker Sanofi's long search for high-growth OTC brands in India finally materialized as it announced the acquisition of Mumbai-headquartered Universal Medicare Pvt. Ltd.'s nutraceutical businesses

You may also be interested in...

In Challenging Times, Sanofi’s Viehbacher Explores New Pricing Models In Emerging Markets

In a rare spotlight opportunity, Sanofi CEO Christopher Viehbacher shares his views on emerging markets during a visit to Mumbai.

Sanofi Inches Closer To Bagging Elder Pharma’s India Business

The French drug maker is close to buying out Elder Pharma’s India business – a move that will give it an undisputable lead in the growing calcium supplement segment.

Deal In Sight For India’s Elder As Race For Calcium Brand Shelcal Picks Up Speed

Global companies, including two Japanese companies, are said to be pitted against each other as they eye Elder Pharma’s most popular brand, calcium supplement Shelcal.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts